Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Apokyn Clear all
Withdrawn Phase 2 Interventional

Low Dose Apomorphine and Parkinsonism

NCT00472355
View directory record Official record
Conditions
Parkinson's Disease
Interventions
apomorphine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
35 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

NCT02469090
View directory record Official record
Conditions
Parkinson Disease, Off Episodes
Interventions
APL-130277, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 4 Interventional Results available

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

NCT01770145
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
Interventions
APOKYN, L-dopa, Trimethobenzamide
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 2 Interventional

JP-1730 to Treat Parkinson's Disease

NCT00040209
View directory record Official record
Conditions
Parkinson Disease
Interventions
JP 1730, IV Levodopa, IV Apomorphine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 3 Interventional

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

NCT00142545
View directory record Official record
Conditions
Parkinson Disease
Interventions
apomorphine HCl injection
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2005 · Synced Sep 1, 2026, 1:41 PM EDT
Suspended Phase 2 Interventional

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

NCT00761228
View directory record Official record
Conditions
Brain Injury
Interventions
Apomorphine, Placebo
Drug
Lead sponsor
NeuroHealing Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

NCT03292016
View directory record Official record
Conditions
Parkinson Disease
Interventions
APL-130277, APO-go, Apokyn
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Boca Raton, Florida • Port Charlotte, Florida • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 1, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

NCT05979415
View directory record Official record
Conditions
Parkinson Disease
Interventions
Apomorphine Cartridge
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
30 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Fountain Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 1, 2026, 1:41 PM EDT
Not listed Phase 4 Interventional

Sublingual Apomorphine in Refractory Restless Legs Syndrome

NCT05529095
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Apomorphine Sublingual Film, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 1, 2026, 1:41 PM EDT
Recruiting No phase listed Observational

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

NCT07219927
View directory record Official record
Conditions
Parkinson Disease
Interventions
Observational study
Other
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Aliso Viejo, California • Irvine, California • Palo Alto, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 1, 2026, 1:41 PM EDT
Terminated Phase 4 Interventional Results available

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

NCT02549573
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms
Interventions
APOKYN, Physical Therapy
Drug · Behavioral
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Examine APL-130277 in Patients With Parkinson's Disease

NCT02228590
View directory record Official record
Conditions
Parkinson's Disease
Interventions
APL-130277
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Sun City, Arizona • Englewood, Colorado • Boca Raton, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 1, 2026, 1:41 PM EDT
Recruiting Phase 1 Interventional

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

NCT07422675
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Interventions
SER-252 (PEOZ-apomorphine), enFuse
Drug · Device
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

NCT00489255
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tigan®, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 1, 2026, 1:41 PM EDT
Withdrawn Phase 2 Interventional

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

NCT00758368
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Apomorphine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 1, 2026, 1:41 PM EDT
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 1, 2026, 1:41 PM EDT
Completed No phase listed Observational

PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00397748
View directory record Official record
Conditions
Volunteer, Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

NCT03187301
View directory record Official record
Conditions
Parkinson's Disease, Off Episodes of Parkinson Disease
Interventions
APL-130277, Placebo, Moxifloxacin
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 1, 2026, 1:41 PM EDT
Recruiting Not applicable Interventional

Motor Network Physiology

NCT04957095
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor
Interventions
Apomorphine Injectable Solution, Subcortical Stimulation
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 3 Interventional

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 1, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

NCT02542696
View directory record Official record
Conditions
Parkinson Disease
Interventions
APL-130277
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 1, 2026, 1:41 PM EDT